Good manufacturing practices production of natural killer cells for immunotherapy: A six-year single-institution experience

Transfusion

Volumn 47, Issue 3, 2007, Pages 520-528

  McKenna Jr , David H ^a   Sumstad, Darin ^b   Bostrom, Nancy ^b   Kadidlo, Diane M ^b   Fautsch, Susan ^b   McNearney, Sarah ^b   DeWaard, Rose ^b   McGlave, Philip B ^b   Weisdorf, Daniel J ^b   Wagner, John E ^b   McCullough, Jeffrey ^b   Miller, Jeffrey S ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; HUMAN SERUM ALBUMIN; INTERLEUKIN 2;

APHERESIS; ARTICLE; CELL FUNCTION; CELL SELECTION; CELL SUSPENSION; CELL VIABILITY; CYTOTOXICITY; GOOD MANUFACTURING PRACTICE; IMMUNOTHERAPY; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL;

ANTIGENS, CD3; ANTIGENS, CD56; BLOOD SPECIMEN COLLECTION; CYTAPHERESIS; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LYMPHOCYTE SUBSETS; RETROSPECTIVE STUDIES;

EID: 33847056957     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2006.01145.x     Document Type: Article

References (31)

1. Chiorean EG, Miller JS. The biology of natural killer cells and implications for therapy of human disease. J Hematother Stem Cell Res 2001;10:451-63.
2. Miller JS. Biology of natural killer cells in cancer and infection. Cancer Invest 2002;20:405-19.
3. Robertson MJ, Ritz J. Biology and clinical relevance of human natural killer cells. Blood 1990;76:2421-38.
4. Lanier LL, Testi R, Bindl J, Philips JH. Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule. J Exp Med 1989;169:2233-8.
5. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001;22:633-40.
6. Ljunggren HG, Karre K. In search of the "missing self": MHC molecules and NK cell recognition. Immunol Today 1990;11:237-44.
7. Carson WE, Fehniger TA, Caligiuri MA. CD56+ bright natural killer cell subsets: characterization of distinct functional responses to interleukin-2 and the c-kit ligand. Eur J Immunol 1997;27:354-60.
8. Fehniger TA, Shah MH, Turner MJ, et al. Differential cytokine and chemokine gene expression by human NK cells following activation IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J Immunol 1999;162:4511-20.
9. Carson WE, Yu H, Dierksheide J, et al. A fatal cytokine-induced systemic inflammatory response reveals a critical role for NK cells. J Immunol 1999;162:4943-51.
10. Ross M, Caligiuri M. Cytokine-induced apoptosis of human natural killer cells identifies a novel mechanism to regulate the innate immune response. Blood 1997;89:910-8.
11. Arase H, Arase N, Saito T. Interferon γ production by natural killer cells and NK1.1+T cells upon NKR-P1 cross-linking. J Exp Med 1996;183:2391-6.
12. Basu S, Sodhi A. Increased release of interleukin-1 and tumor necrosis factor by interleukin-2-induced lymphokine-activated killer cells in the presence of cisplatin and FK-565. Immunol Cell Biol 1992;70:15-24.
13. Warren HS, Kinnear BF, Philips JH, Lanier LL. Production of IL-5 by human NK cells and regulation of IL-5 secretion by IL-4, IL-10, and IL-12. J Immunol 1995;154:5144-52.
14. Saito S, Kasahara T, Sakakura S, et al. Interleukin-8 production by CD16-CD56 bright natural killer cells in the human early pregnancy deciduas. Biochem Biophys Res Commun 1994;200:378-83.
15. Levitt LJ, Nagler A, Lee F, et al. Production of granulocyte/macrophage- colony-stimulating factor by human natural killer cells: modulation by the p75 subunit of the interleukin-2 receptor and by the CD2 receptor. J Clin Invest 1991;88:67-75.
16. Middleton D, Curran M, Maxwell L. Natural killer cells and their receptors. Transplant Immunol 2002;10:147-64.
17. Dutcher J, Gaynor E, Boldt D, et al. A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma. J Clin Oncol 1991;9:641-8.
18. Margolin K, Rayner A, Hawkins M, et al. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J Clin Oncol 1989;7:486-98.
19. Ishikawa E, Tsuboi K, Saijo K, et al. Autologous natural killer cell therapy for human recurrent malignant glioma. Anticancer Res 2004;24:1861-71.
20. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002;295:2097-100.
21. Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005;105:3051-7.
22. Burns LJ, Weisdorf DJ, DeFor TE, et al. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial. Bone Marrow Transplant 2003;32:177-86.
23. McKenna D, Kadidlo D, Miller J, et al. The Minnesota Molecular & Cellular Therapeutics Facility: a state-of-theart biotherapeutics engineering laboratory. Transfus Med Rev 2005;18:217-28.
24. Miller JS, Oelkers S, Verfaillie C, McGlave P. Role of monocytes in the expansion of human activated natural killer cells. Blood 1992;80:2221-9.
25. Mascotti K, McCullough J, Burger SR. HPC viability measurement: trypan blue versus acridine orange and propidium iodide. Transfusion 2000;40:693-6.
26. Hirayama M, Genyea C, Brownell A, Kaplan J. IL-2-activated murine newborn liver NK cells enhance engraftment of hematopoietic stem cells in MHC-mismatched recipients. Bone Marrow Transplant 1998;21:1245-52.
27. Koh C, Blazar B, George T, et al. Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo. Blood 2001;97:3132-7.
28. Skeate RC, Miller JS, Eubanks J, et al. Acute hemolytic transfusion reaction due to anti-A in a type-A patient who received type-A red cells: passenger lymphocyte syndrome post-NK cell infusion? [abstract]. Cytotherapy 2005;7(Suppl 1):132.
29. Passweg JR, Stern M, Koehl U, et al. Use of natural killer cells in hematopoietic stem cell transplantation. Bone Marrow Transplant 2005;35:637-43.
30. Miller JS, Prosper F, McCullar V. Natural killer (NK) cells are functionally abnormal and NK cell progenitors are diminished in G-CSF-mobilized peripheral blood progenitor cell collections. Blood 1997;90:3098-105.
31. Uharek L, Hilbers U, Hartung G, et al. Cellular immunotherapy with alloreactive NK cells: promising results of a phase I/II study investigating the use of ex-vivo activated donor CD3-CD56+ NK cells after transplantation of highly purified HLA-haplotype mismatched stem cell grafts in patients. Onkologie 2003;26(S5):38.